» Articles » PMID: 20217258

Clinical Significance of CEA and CA19-9 in Postoperative Follow-up of Colorectal Cancer

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2010 Mar 11
PMID 20217258
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We evaluated the efficiency of CEA and CA19-9 as tools for diagnosing recurrence in the postoperative surveillance of colorectal cancer.

Materials And Methods: A total of 227 patients who underwent curative resection for colorectal cancer between 1999 and 2003 at our hospital received complete follow-up according to the schedule determined prospectively. Using receiver operating characteristic (ROC) analysis, performance of postoperative values of CEA or CA19-9 for detecting recurrence was assessed.

Results: The sensitivity (1.000) and specificity (0.978) of the postoperative values of CEA in the high preoperative CEA group were very high. Even in the normal preoperative CEA group, the area under the curve (AUC) of the ROC curve of CEA (0.740, 95% confidence interval [95% CI], 0.628-0.852) was significantly larger than 0.5 (P < 0.001). The postoperative values of CA19-9 showed high sensitivity (0.833) and specificity (0.900) in the high preoperative CA19-9 group, while the AUC of the ROC curve of the normal preoperative group was as small as 0.510 (95% CI, 0.376-0.644). In the high preoperative CA19-9 group, however, there was no significant difference between the AUC of CA19-9 (0.904, 95% CI, 0.786-1.000) and that of CEA (0.869, 95% CI, 0.744-0.994) (P = 0.334).

Conclusions: The measurement of CEA is an efficient way to detect recurrence. The efficiency of measuring CA19-9 for the purpose of detecting recurrence is low, especially in patients with a normal level of preoperative CA19-9. Even in patients with a high preoperative level of CA19-9, CEA might be able to fill the role of CA19-9.

Citing Articles

Conditional survival and the prognostic value of serum carcinoembryonic antigen level in oldest old with colorectal cancer.

He W, Yang Y, Liu Q, Luo D, Li Q, Li X BMC Gastroenterol. 2024; 24(1):220.

PMID: 38987680 PMC: 11234783. DOI: 10.1186/s12876-024-03318-4.


Diagnostic Performance of F-18 FDG PET/CT in the Detection of Recurrent Colorectal Cancer: Correlation with Biochemical Markers and Conventional Imaging Modalities.

Mihailovic J, Roganovic J, Starcevic I, Nikolic I, Prvulovic Bunovic N, Nikin Z J Clin Med. 2024; 13(12).

PMID: 38930131 PMC: 11204678. DOI: 10.3390/jcm13123602.


Prognostic prediction model of colorectal cancer based on preoperative serum tumor markers.

Diao Y, Rao S, Shu X, Cheng Y, Tan C, Wang L World J Gastrointest Surg. 2024; 16(5):1344-1353.

PMID: 38817280 PMC: 11135305. DOI: 10.4240/wjgs.v16.i5.1344.


Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.

Jakab A, Patai A, Darvas M, Tormassi-Bely K, Micsik T Pathol Oncol Res. 2024; 30:1611574.

PMID: 38645565 PMC: 11026638. DOI: 10.3389/pore.2024.1611574.


Association of preoperative and recurrent serum carcinoembryonic antigen and outcome of colorectal cancer patients with metastatic relapse.

Tong S, Wu R, Zhang L, Lu P, Hu X, Li Y Heliyon. 2024; 10(7):e29347.

PMID: 38617920 PMC: 11015133. DOI: 10.1016/j.heliyon.2024.e29347.